INSCRIPTA® ACQUIRES INFINOME BIOSCIENCES AND SESTINA BIO TO ADVANCE SUSTAINABLE BIOMANUFACTURING
Summary
"Tackling the unprecedented opportunity to improve global health and sustainability through biomanufacturing requires a strong combination of talent, experience, technology, and commercial assets," said Sri Kosaraju, CEO, Inscripta. "With our platform, we are able to create industrially optimized strains faster and at a fraction of the resource and infrastructure costs traditionally required for commercialization of precision fermentation solutions," said Infinome co-founder and CEO/CTO Dr. Richard Fox. "The proprietary methods we are developing enable us to produce and understand orders of magnitude more biological data than other synbio platforms," said Ted Tarasow, CTO, Sestina Bio. "Our approach to minimal strain design combined with Inscriptas unique genome editing capabilities will enable dramatic reductions in the time and cost of bringing products to market," added Andrew Horwitz, Vice President of R&D, Sestina Bio.With the addition of Infinome and Sestina Bio, Inscripta is building on its history of technological innovation and has already begun applying its cutting-edge technologies to develop products for a diverse set of large industrial and consumer markets. Separately, Inscripta is engaging in commercial conversations around the previously announced development of a ready-to-scale microbial strain producing Bakuchiol, a natural retinol replacement.Inscripta\xae is a life science technology company committed to creating a cleaner, healthier, and more sustainable world through biomanufacturing.